Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

Emmanouil N. Rizos 2nd Psychiatric Department, Medical School, National Kapodistrian University of Athens, “Attikon” General Hospital, Athens, GreeceCorrespondence[email protected]

, MD,

Athanasia Papadopoulou Tarsi Psychiatric Department, Athens Psychiatric Hospital “Dromokaition”, Athens, Greece

Efstathios Laskos Biochemistry and Microbiology Department, Athens Psychiatric Hospital “Dromokaition”, Athens, Greece

Panagiota G. Michalopoulou 2nd Psychiatric Department, Medical School, National Kapodistrian University of Athens, “Attikon” General Hospital, Athens, Greece; CSI Laboratory, Department of Psychiatry, Institute of Psychiatry, London, UK

Anastasia Kastania Bioinformatics and Medical Informatics Team, Biomedical Research Foundation, Academy of Athens, Athens, Greece

Dimitrios Vasilopoulos Biochemistry and Microbiology Department, Athens Psychiatric Hospital “Dromokaition”, Athens, Greece

Konstantinos Katsafouros Tarsi Psychiatric Department, Athens Psychiatric Hospital “Dromokaition”, Athens, Greece

Lefteris Lykouras 2nd Psychiatric Department, Medical School, National Kapodistrian University of Athens, “Attikon” General Hospital, Athens, Greece

show all

Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date